Stockholm Stock Exchange | Mid Cap
Bioarctic
+89.24%
Latest
-
3 months
Goldman SachsDNBRBCRX SecuritiesCarnegieKempenNordea MarketsDNB Markets

Price Targets For Bioarctic

AnalystPrice TargetDateUpside
Goldman Sachs278 SEKAug 30
+89.24%
DNB270 SEKAug 30
RBC290 SEKJul 30
RX Securities290 SEKJul 29
Carnegie370 SEKFeb 15
Kempen350 SEKNov -23
Nordea Markets356 SEKNov -22
DNB Markets250 SEKJul -21

About The Company

BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of disorders that affect the Central Nervous System. These types of treatments are commonly referred to as “disease modifiers”. They affect the underlying disease pathology and can hopefully stop or significantly delay disease progression.
Bioarctic